A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04150575 |
Recruitment Status :
Active, not recruiting
First Posted : November 5, 2019
Last Update Posted : March 19, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cervical Cancer | Drug: HLX10+Albumin-Bound Paclitaxel | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 143 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Single-Arm, Open-Label, Multicentre, Phase II Clinical Study to Evaluate Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy |
Actual Study Start Date : | March 10, 2020 |
Estimated Primary Completion Date : | June 15, 2021 |
Estimated Study Completion Date : | September 15, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: HLX10
HLX10+albumin-bound paclitaxel
|
Drug: HLX10+Albumin-Bound Paclitaxel
HLX10: 4.5 mg/kg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and HLX10 for up to 2 years.
Other Name: HLX10 is an innovative monoclonal antibody targeting PD-1,developed by Shanghai Henlius Biotech, Inc. |
- ORR [ Time Frame: up to 2 years ]Objective response rate(assessed by independent radiological review committee (IRRC) based on the RECIST Version 1.1)
- ORR [ Time Frame: up to 2 years ]Objective response rate (ORR) (assessed by IRRC as per iRECIST, and by the investigator as per RECIST v1.1 and iRECIST, respectively)
- PFS [ Time Frame: from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years ]Progression-free survival (PFS) (assessed by IRRC and the investigator as per RECIST v1.1 and iRECIST, respectively)
- 6-month PFS rate [ Time Frame: from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 6 months ]6-month progression-free survival rate
- OS [ Time Frame: from the date of first dose until the date of death from any cause,assessed up to 2 years ]Overall survival
- 6-month OS rate [ Time Frame: from the date of first dose until the date of 6-month ]6-month overall survival rate

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Gender Based Eligibility: | Yes |
Gender Eligibility Description: | female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Voluntarily participate and have signed the informed consent form (ICF);
- Aged ≥ 18 years and ≤ 75 years at the time of signing the ICF
- Patients histologically or cytologically diagnosed with cervical cancer (pathology report is required and pathological types are cervical squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma).
-
Patients with advanced cervical cancer who have experienced progressive disease or relapse after receiving standard treatment (first-line chemotherapy must be included) or who are intolerant to first-line chemotherapy. First-line chemotherapy includes any of the following:
- Platinum-based drugs + taxanes;
- Platinum-based drugs + topotecan;
- Taxanes + topotecan.
- The radiological examination during screening confirms the presence of at least one measurable lesion evaluated according to the RECIST v1.1(IRRC).
- Patients whose tumour specimens are tested positive for PD-L1 expression (CPS ≥ 1).
- An ECOG score of 0 or 1.
- Conforming to laboratory measurements;
Exclusion Criteria:
- Patients who have previously received albumin-bound paclitaxel.
- Patients with other active malignancies within 5 years or at the same time.
- Patients who are preparing for or have received an organ or bone marrow transplant.
- Presence of uncontrollable pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
- Central nervous system (CNS) or leptomeningeal metastases confirmed by imaging or pathological examination.
- Class III to IV cardiac insufficiency according to NYHA classification or an LVEF (left ventricular ejection fraction) < 50% by cardiac colour Doppler.
8.With human immunodeficiency virus (HIV) infection. 9.With active pulmonary tuberculosis. 10.Have received any T-cell costimulatory or immune checkpoint therapy, including but not limited to cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitors, PD-1 inhibitors, PD-L1/2 inhibitors, or other agents that target T cells.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04150575
China | |
Cancer Hospital, Chinese Academy of Medical Sciences | |
Beijing, China |
Principal Investigator: | lingying wu | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Responsible Party: | Shanghai Henlius Biotech |
ClinicalTrials.gov Identifier: | NCT04150575 |
Other Study ID Numbers: |
HLX10-011-CC201 |
First Posted: | November 5, 2019 Key Record Dates |
Last Update Posted: | March 19, 2021 |
Last Verified: | October 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Uterine Cervical Neoplasms Disease Progression Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Neoplasms Uterine Cervical Diseases Uterine Diseases Disease Attributes |
Pathologic Processes Paclitaxel Albumin-Bound Paclitaxel Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action |